Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Verona initiates Phase II trial for COPD powder inhaler

Verona has announced the start of Phase II clinical trial to evaluate the pharmacokinetic profile, efficacy, and safety of a dry powder inhaler formulation of RPL554, for use in patients with moderate to severe chronic obstructive pulmonary disease.

December 17th, 2018|News|

Breathe Easier with AstraZeneca Fasenra?

IEBS - breathe-easier-with-astrazeneca-fasenra

Chronic obstructive pulmonary disease, or COPD, is a chronic inflammatory disease that causes a cough with mucus, wheezing, shortness of breath or chest tightness, all of which make breathing difficult. […]

May 25th, 2018|Blog|